Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of artemisinin-typed compound in preparation of drug for treating and preventing hyperlipidemia

A technology of artemisinin and compounds, applied in the field of preparation of artemisinin-like compounds for the treatment and prevention of hyperlipidemia drugs, to achieve the effects of strong pharmacological effects, safe drug selection, and low price

Active Publication Date: 2015-03-11
SHANGHAI JIAO TONG UNIV
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the application of artemisinin and its derivatives in reducing blood lipid and anti-atherosclerosis has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of artemisinin-typed compound in preparation of drug for treating and preventing hyperlipidemia
  • Application of artemisinin-typed compound in preparation of drug for treating and preventing hyperlipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1, high-fat diet feeds rats to form lipid metabolism disorder model

[0025] 70 male SD rats, weighing 160-180 g, were fed for 5 days adaptively. The animals were stratified according to body weight and randomly divided into 7 groups with 10 rats in each group. The high-fat feed ratio is as follows: 10% lard, 2% cholesterol, 0.2% propylthiouracil, 0.5% pig bile salt, and 87.3% basal feed. The animals were fed with high-fat feed for modeling (except the normal group) and were given artemisinin or its derivatives for 19 consecutive days. On the 20th day, the rats were anesthetized with 25% urethane (0.4ml / 100g), blood was collected through the abdominal aorta, and the serum was centrifuged to measure triglyceride (TG), cholesterol (CHO), high-density lipoprotein (HDL-C ), low-density lipoprotein (LDL-C), the results are shown in Table 1 and Table 2, as can be seen from Table 1, artemisinin and its derivatives can significantly reduce triglyceride and cholest...

Embodiment 2

[0034] Embodiment 2, New Zealand white rabbit fed with high-fat diet forms atherosclerosis model

[0035] 70 male New Zealand white rabbits, weighing 2kg, were fed for 7 days adaptively. The animals were stratified according to body weight and randomly divided into 7 groups with 10 rabbits in each group. The animals were fed with high-fat feed for modeling (except the normal group) and were given artemisinin or its derivatives for 2 consecutive months. After the experiment, blood was collected through the ear vein, and the serum was centrifuged to measure TG and CHO. The experimental results are shown in Table 3. It can be seen from Table 3 that artemisinin and its derivatives can significantly reduce TG and CHO in the serum of high-fat white rabbits. Among them, the effect of artemisinin and its derivatives on reducing triglycerides was significantly better than that of atorvastatin group, and the effect of artesunate was the best; the aorta and liver were separated, and oi...

Embodiment 3

[0041] Artesunate 10g, hydroxypropyl methylcellulose 80g, polyvinylpyrrolidone 100g, lactose 85g, micronized silica gel 100g.

[0042]Mix the prescribed amount of artesunate with the slow-release agent (hydroxypropyl methylcellulose and lactose), add the binder polyvinylpyrrolidone plasmid, dry at 40°C to 80°C, and dry the granules. Add the prescribed amount of lubricant micro-powder silica gel to the granules, mix well, and punch out shaped tablets. Dihydroartemisinin, artesunate, and artemether can all be prepared into tablets of corresponding specifications with reference to Example 3.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of an artemisinin-typed compound in preparation of a drug for treating and preventing hyperlipidemia. The artemisinin-typed compound is artemisinin, artesunate, dihydroartemisinin or artemether. The artemisinin-typed compound can be prepared into any pharmaceutically-acceptable preparation. The invention develops new medical applications of the artemisinin-typed compound. The application overcomes defect of a drug for treating and preventing the hyperlipidemia in the prior art. The drug can achieve a treatment effect from inflammatory resistance and blood fat reducing. Meanwhile, the artemisinin-typed compound is a drug which is firstly developed in our country, which means that our country is a main producing country, so that the artemisinin-typed compound is wide in sources and is low in price. In addition, the artemisinin-typed compound is strong in pharmacologic action, is high in safety, and provides an economical and safe drug for patients suffered from cardiovascular diseases.

Description

[0001] This application is a divisional application with the application number 201310124062.9, the filing date is 2013.04.10, and the invention name is "Use of Artemisia Compounds in the Preparation of Anti-Atherosclerotic Drugs". technical field [0002] The invention relates to the field of biomedicine, in particular to the use of artemisinin compounds in the preparation of medicines for treating and preventing hyperlipidemia. Background technique [0003] Atherosclerosis (AS) is a common cardiovascular disease in modern society, mainly manifested as lipid deposition in the arterial intima, focal fibrosis in the intima, and formation of atherosclerotic plaques, resulting in hardening of the vessel wall and the deterioration of the lumen. Stenosis, and then cause a series of secondary lesions, especially easy to cause ischemic diseases in cardiovascular and cerebrovascular, etc., is the number one killer of human beings in today's society. The pathogenesis of atheroscleros...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61K31/357A61P3/06
CPCA61K31/357A61K31/366
Inventor 王玉亮唐克轩孙小芬
Owner SHANGHAI JIAO TONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com